Partners

BASE scientists are collaborating with Vaxxas to develop needle-free mRNA vaccines using high-density microarray patch (HD-MAP) technology.

The partnership was awarded the BARDA Patch Forward Prize by the US Department of Health and Human Services to deliver mRNA vaccines via a small nanopatch. This approach avoids needles and cold-chain storage, with the potential to improve vaccine access worldwide.

With support from Sanofi, the Australian and Queensland Governments, BASE has established end-to-end mRNA-LNP production facilities to help Australian researchers develop new mRNA medicines.

This infrastructure supports both academic and industry partners progressing mRNA-LNP candidates, from initial design through to the clinic.

BASE has partnered with Sartorius, a global leader in bioprocess technology, to co-develop protocols and technologies that improve the quality and yield of mRNA synthesis.

The collaboration combines BASE’s advanced mRNA analytics and with Sartorius biomanufacturing expertise to improve large-scale mRNA synthesis.

BASE has partnered with Oxford Nanopore Technologies to develop nanopore sequencing methods for the quality analysis of mRNA medicines.

Using nanopore sequencing, individual mRNA molecules can be analysed in real time as they pass through a protein channel, providing direct measurement of sequence identity and integrity. This approach enables rapid, comprehensive quality control of mRNA medicines from research through to clinical manufacture.

BASE is a core facility within the national RNA Products capability supported by Therapeutic Innovation Australia (TIA), part of Australia’s National Collaborative Research Infrastructure Strategy (NCRIS).

TIA invests in translational research infrastructure, such as the BASE facility, to connect researchers with the expertise and services needed to develop new mRNA medicines.